Skip to main content

Table 1 Clinical characteristics of the patients with SLE in the study

From: Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis

  Inactive SLE (N = 80) Active non-renal SLE (N = 67) Active renal SLE (N = 80) Total (N = 227) P value*
Mean ± SD; number (%)  
Age, years 44.0 ± 12.4 35.1 ± 13.9 37.8 ± 13.9 39.2 ± 13.8 < 0.001
Women 77 (96) 62 (93) 75 (94) 214 (94) 0.37
SLE duration, years 12.5 ± 6.6 4.0 ± 5.2 4.9 ± 5.8 7.3 ± 7.0 < 0.001
Clinical disease activity
 Neuropsychiatric - 9 (13) 5 (6.3) 14 (6.2) 0.14
 Musculoskeletal - 30 (45) 29 (36) 59 (26) 0.29
 Renal - 0 (0) 80 (100) 80 (35) < 0.001
 Mucocutaneous - 37 (55) 26 (33) 63 (28) 0.006
 Serositis - 15 (22) 14 (18) 29 (13) 0.46
 Hematological - 39 (58) 19 (24) 58 (26) < 0.001
Autoantibodies
 Anti-Sm 12 (15) 21 (31) 21 (26) 54 (24) 0.06
 Anti-Ro 48 (60) 44 (66) 57 (71) 149 (66) 0.37
 Anti-La 11 (14) 15 (22) 27 (34) 53 (23) 0.01
 Anti-nRNP 20 (25) 28 (42) 30 (38) 78 (34) 0.09
 aPLa 31 (39) 27 (40) 18 (23) 76 (33) 0.04
SLEDAI 2.11 ± 1.67 10.1 ± 5.51 16.0 ± 6.42 9.39 ± 7.65 < 0.001
PGA score 0.21 ± 0.15 1.89 ± 0.32 2.14 ± 0.21 1.39 ± 0.90 < 0.001
SLICC damage score 0.49 ± 1.20 0.69 ± 0.97 0.81 ± 1.32 0.77 ± 1.18 0.98
Medications at time of sample collection
 Prednisolone 38 (48) 27 (40) 41 (51) 106 (47) 0.41
 Azathioprine 30 (38) 8 (12) 16 (20) 54 (24) 0.001
 Cyclophosphamide 0 (0) 1 (1.5) 1 (1.3) 2 (0.9) 0.57
 Cyclosporin A 3 (3.8) 2 (3) 3 (3.8) 8 (3.5) 0.96
 Tacrolimus 2 (2.5) 3 (4.5) 2 (2.5) 7 (3) 0.73
 Mycophenolate mofetil 12 (15) 6 (9) 11 (14) 29 (13) 0.52
 Hydroxychloroquine 48 (60) 33 (49) 35 (44) 116 (51) 0.11
  1. SLE systemic lupus erythematosus, SD standard deviation, SLEDAI SLE disease activity index, aPL antiphospholipid, PGA physician’s global assessment, SLICC SLE International Collaborative Clinic
  2. *P comparison among the three groups
  3. aEither IgG anti-cardiolipin or the lupus anticoagulant